On January 11, 2022 Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, reported that Kineta’s management team has been invited to participate at H.C. Wainwright Bioconnect Virtual Conference that is being held on January 10-13, 2022 (Press release, Kineta, JAN 11, 2022, View Source;utm_medium=rss&utm_campaign=kineta-to-present-at-the-h-c-wainwright-bioconnect-virtual-conference [SID1234598576]). Shawn Iadonato, Kineta Chief Executive Officer, will present a corporate overview that will be available on-demand from January 10-13 to attendees registering via H.C. Wainwright at View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!